Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00618657 · ClinicalTrials.gov registry record · Phase 2
Carboplatin+Nab-paclitaxel, Plus Trastuzumab (HER2+) or Bevacizumab (HER2-) in the Neoadjuvant Setting
A Phase 2 study, sponsored by University of California, Irvine.
- Completed
- Registry status
- Phase 2
- Development phase
- 127
- Enrollment target
NCT00618657 is a Phase 2 study that has completed, run by University of California, Irvine. The registered enrollment target is 127 participants.
The verdict
NCT00618657, a Phase 2 study, has completed, sponsored by University of California, Irvine.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 127 participants
- Enrollment target
Study Summary
This phase II is studying the side effects and how well carboplatin and paclitaxel albumin-stabilized nanoparticle formulation when together with bevacizumab or trastuzumab before surgery works in treating patients with stage I-III breast cancer. Drugs used in chemotherapy, such as carboplatin and paclitaxel albumin-stabilized nanoparticle formulation, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Monoclonal antibodies, such as bevacizumab and trastuzumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Giving more than one drug (combination chemotherapy) and monoclonal antibody therapy together before surgery may make the tumor smaller and reduce the amount of normal tissue that needs to be removed.
Interventions
- DRUG Carboplatin
- DRUG bevacizumab
- DRUG trastuzumab
- DRUG paclitaxel albumin-stabilized nanoparticle formulation
- PROCEDURE magnetic resonance imaging
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 127 participants |
| Start Date | 2008-02 |
| Est. Completion | 2021-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00618657
The ClinicalTrials.gov registry entry for NCT00618657 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 127 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of California, Irvine, which has 368 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Carboplatin is the first listed.
NCT00618657 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00618657 about?
NCT00618657 is a clinical study titled "Carboplatin+Nab-paclitaxel, Plus Trastuzumab (HER2+) or Bevacizumab (HER2-) in the Neoadjuvant Setting". This phase II is studying the side effects and how well carboplatin and paclitaxel albumin-stabilized nanoparticle formulation when together with bevacizumab or trastuzumab before surgery works in treating patients with stage I-III breast cancer. Drugs used in chemotherapy, such as carboplatin and p...
What is the current status of trial NCT00618657?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 127 participants. The study started on 2008-02. Estimated completion is 2021-07.
What interventions are being tested in trial NCT00618657?
The interventions under investigation include: Carboplatin (DRUG), bevacizumab (DRUG), trastuzumab (DRUG), paclitaxel albumin-stabilized nanoparticle formulation (DRUG), magnetic resonance imaging (PROCEDURE).
Who is sponsoring clinical trial NCT00618657?
This trial is sponsored by University of California, Irvine, which has 368 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.